Effect of Home Enteral Nutrition on Nutritional Status, Body Composition and Quality of Life in Patients With Malnourished Intestinal Failure

Xuejin Gao 1, Yupeng Zhang 1, Li Zhang 1, Sitong Liu 1, Hao Liu 2, Da Zhou 1, Jieshou Li 1 and Xinying Wang 1*

1 Affiliated Jinling Hospital, Research Institute of General Surgery, Medical School of Nanjing University, Nanjing, China, 2 Affiliated Jinling Hospital, Research Institute of General Surgery, Southern Medical University, Guangzhou, China

Background: The ultimate goal of intestinal failure (IF) management is to maintain optimal nutritional status, improve the quality of life (QoL), and promote intestinal adaptation. Enteral nutrition support is safe and effective in patients with IF and plays a central role in the management of patients with IF. The purpose of this study was to evaluate the effect of home enteral nutrition on nutritional status, body composition (BC), QoL and other clinical outcomes in malnourished patients with intestinal failure.

Methods: This prospective observational study included 166 malnourished patients with intestinal failure presented to Jinling Hospital from January 2016 to October 2018. All patients were supported with home enteral nutrition after discharge. We evaluated clinical outcomes, including nutritional status, body composition (BC), phase angle (PhA), QoL, mortality, gastrointestinal complications related to enteral feeding, and other clinical outcomes at 1, 3, and 6 months after discharge.

Results: Body weight, BC, and other nutritional parameters were maintained or significantly increased during the period of home enteral nutrition after discharge ($p < 0.01$). Especially, the quality of skeletal muscle mass in body composition was significantly improved ($p < 0.01$). SF-36 quality of life scores was significantly improved (discharged at 6 months: reported health transition 40.7 ± 12.1 vs. 69.3 ± 16.3, $p < 0.01$). There were no differences between hospital and out of hospital with respect to tube-related or gastrointestinal complications. Advanced age, disease type, and poor nutritional outcomes were risk factors for poor clinical outcomes.

Conclusions: Home enteral nutrition support is effective for malnourished patients with intestinal failure. It improves nutritional status, BC, PhA, and QoL.

Clinical Trial Registration: identifier: ChiCTR2000035145.

Keywords: intestinal failure, home enteral nutrition, quality of life, nutritional status, phase angle
INTRODUCTION

Intestinal failure (IF), a rare type of organ failure, is defined as “the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation (IVS) is required to maintain health and/or growth” (1). Based on the onset, metabolic and expected outcome criteria, the functional classification of IF including Type I (acute, short-term, and usually self-limiting condition), Type II (prolonged acute condition), and Type III (chronic condition) (2).

The goal of IF management is to maintain optimal nutritional status, reduce complications, improve quality of life, and promote intestinal adaptation or enteral autonomy (2–4). In the case of patients with intestinal dysmotility or an intestinal mechanical obstruction mainly depend on parenteral nutrition to sustain life, due to insufficient intestinal nutrition. Although, PN is a life-saving therapy for patients with IF (5, 6). Long-term use of PN is associated with many complications (5), including PN-associated liver disease, catheter-related infections, thrombosis and metabolic complications (5–8). At present, it is accepted that enteral nutrition (EN) can enhance the intestinal adaptation in patients with IF (9). Therefore, EN should be started as soon as possible the gut is functional. Compared with parenteral nutrition, enteral nutrition as a preferred option has the advantages of being more economical, more convenient, and safer. Furthermore, enteral feeding conforms to physiological functions, which could protect the gastrointestinal barrier, immune function, and motility (10). Therefore, it is important for IF patients to successfully implement EN feeding to significantly improve the intestinal rehabilitation process and the patient’s QoL (5).

Home enteral nutrition (HEN) therapy delivers nutrients and/or fluids to the gastrointestinal tract (GI) through tube or stoma to patients who are medically stable and unable to meet oral nutrition (11). Since its introduction in the 1970s, HEN has been identified as a reliable and effective nutritional intervention (12). Enteral nutrition is started during a hospital stay and continued as a long-term home enteral nutrition therapy (12), which is only minor different from the indication for hospital enteral nutrition.

Nutritional support treatment is usually indicated in patients who are malnourished or at high risk of malnutrition in the hospital. When the patients discharged from the hospital, HEN can be used as a supplementary life-sustaining therapy (12) and can be maintained or even saved the lives patients who unable to meet energy needs via daily oral intake (13, 14). Home enteral nutrition improves prognosis in patients with severe chronic diseases and allows the integration of patients with their families and society (15), thereby improving QoL (12). Moreover, it is associated with improved health outcomes, lower readmission rates, and reduced medical costs (16, 17). EN is safe and effective for patients with IF (18) and plays a central role in the management of patients with intestinal failure (3). For these reasons, as a cost-effective and reliable complementary treatment method, home enteral nutrition is also quite essential for patients with IF who need nutritional support after discharged. HEN combined with home parenteral nutrition can prevent further deterioration of the nutritional status in malnourished patients with IF. However, large sample prospective studies specifically aimed at investigating the effects of home enteral nutrition in malnourished patients with IF are lacking.

Therefore, the main purpose of this study was to determine the effect of HEN on nutritional status, body composition, phase angle (PhA), quality of life, and physiological function in malnourished patients with IF.

MATERIALS AND METHODS

Study Design and Ethics Approval

The protocol for this prospective observational study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the Research Ethics Committee of the Jinling Hospital. In accordance with the Austrian law and Research Ethics Committee guidelines, all participants or their guardians obtained written informed consent. The trial was registered at Chinese Clinical Trial Registry (ChiCTR2000035145).

Patients and Setting

The data of 166 patients who received HEN treatment in the Clinical Nutrition Treatment Center of Jinling Hospital from January 2016 to October 2018 were analyzed. Patients receive appropriate HEN treatment according to standard protocols from the nutrition support team.

The definition of intestinal failure is as described above, according to ESPEN guidelines (1). Malnutrition is defined according to the 2015 ESPEN Consensus Statement (19). Adult patients with IF were eligible if they met the following inclusion criteria: age ≥18 years; inability to meet nutritional requirements orally; estimated duration of enteral nutrition therapy at home for at least 4 weeks; stable clinical status; patient and family acceptance; and appropriate and safe home environment. Exclusion criteria included contraindication for enteral nutrition; life expectancy of fewer than 2 months; pregnancy; severe renal or liver dysfunction; participation in another clinical study; and inability or unwillingness to provide informed consent.

Standardized enteral nutrition was provided according to a nutritional protocol. The energy requirement target was calculated based on actual body weight as 25–30 kcal/kg, and protein requirements ranged from 1.0 to 1.5 g/kg/day. Before being discharged from the hospital, members of the nutrition team will train caregivers who would assist them at home (family members or informal caregivers) to implement HEN therapy (20). The specific training content mainly includes the safe utilization of the infusion pump, proper use and storage of enteral feeding formulas, the management of drugs and water through enteral feeding devices, and the protection of tube position (21).

Nutrition support team members followed up on patients once a month. The home visiting staff performed physical examinations and assessments of each patient following standard procedures.

During each home visit, assessments included body weight, body composition, blood pressure, blood glucose, and QoL using the SF-36 Health Survey.
In the standard protocol, we define the conditions and cut-off values for the diagnosis of HEN treatment complications. Gastrointestinal complications (GIC) were defined as follows: constipation: despite the use of constipation drugs, no bowel movement for more than 3 days; abdominal distension: abdominal changes during the physical examination with tympany and/or no bowel sounds; diarrhea: loose and watery bowel movements (stools), with more than three stools per day; vomiting: enteral formula ejected through the mouth; and aspiration: diet presence in the airway or respiratory tract (with or without exteriorization) (21, 22). Metabolic complications were defined as follows: hyperglycemia (>11.1 mmol/L) and hypoglycemia (<4.4 mmol/L); hypernatremia (>150 mmol/L); hyponatremia (<136 mmol/L); hyperkalemia (>5.5 mmol/L); hypokalemia (<3.5 mmol/L); high blood urea nitrogen levels (>405 mg/dl); and dehydration based on clinical signs, such as oliguria (<400 mL urine/day) (21). The hospital physician specialized in clinical nutrition undertook the prevention and treatment of GIC and metabolic complications, high blood urea nitrogen levels, and dehydration after notification by the home visiting staff (21).

When tube-related complications occurred, including displacement, occlusion and breakage, infection around the wound exit site, and the presence of granulation tissue, home visiting staff diagnosed them and when possible addressed them directly at the patients’ homes (21).

Bioelectrical Impedance Analysis
In Body S10 (InBody Co, Ltd., Seoul, South Korea) was selected to perform BIA measurement to assess body composition. The device has a tetrapolar eight-point contact electrode system that contains six different Frequency (1, 5, 50, 250, 500, and 1,000 kHz) (23). The patient is required to fasting and keep the quiescent condition for 3 h in advance, and then take a supine position during the measurement, with both hands placed on both sides of the body’s midline (23). PhA derived from BIA was determined as follows: \( \text{PhA} = \arctangent \left( \frac{\text{reactance}}{\text{resistance}} \right) \times \left( \frac{180}{\pi} \right) \). Reactance and resistance were measured at 50 kHz (24).

Laboratory Analysis
Blood samples were drawn in the morning after overnight fasting. Hemoglobin, serum levels of albumin, prealbumin, transferrin, retinol binding protein, fibronectin, insulin-like growth factor I (IGF-1), liver enzymes and bilirubin, electrolytes, urea nitrogen, and creatinine were measured using routine methods at the Department of Laboratory Medicine, Jinling Hospital or the local hospital laboratory.

Data Collection
All participants of baseline data collection are starting home enteral nutrition treatment, including demographic data (age, gender, primary disease, etc.), information about nutrition therapy, nutritional status, body composition, PhA, and QoL. The implementation of enteral feeding relies on infusion pump or gravity infusion.

Information on the frequencies and types of complications associated with HEN therapy, nutritional status, body composition, PhA, quality of life, and the clinical outcomes of the HEN therapy (death, moving from tube-feeding to oral feeding, and work status) was collected during hospitalization and at 1, 3, and 6 months after discharge.

Data Analyses
Patient characteristics are displayed by descriptive statistics, and then statistical methods are selected according to the data type and distribution status. Continuous variables are expressed as mean ± SD or median and range, and categorical variables are expressed as absolute values and relative frequencies. The incidence rates of complications were compared for inpatients and outpatients using the chi-square test. Nutritional status,
### TABLE 1 | Patients and disease characteristics at baseline.

| Variable                                      | Range             |
|-----------------------------------------------|-------------------|
| Total no. of patients                        | 166               |
| Age (years)                                  | 46.2 ± 16.5       |
| Male/female                                  | 70/96             |
| Height (cm)                                  | 165.8 ± 7.8       |
| Weight (kg)                                  | 49.4 ± 10.8       |
| BMI kg/m²                                    | 17.9 ± 3.4        |
| Duration after diagnosis of IF (months), median (IQR) | 3 (1.5–22)       |
| Functional classification                     |                   |
| Type II (prolonged acute)                    | 24 (14.5)         |
| Type III (chronic)                           | 142 (85.5)        |
| Pathophysiological classification            |                   |
| Short bowel syndrome                         | 43 (25.9)         |
| Mesenteric infarction (arterial or venous thrombosis) | 20               |
| Crohn’s disease                              | 8                 |
| Radiation enteritis                          | 6                 |
| Surgical complications                       | 5                 |
| Intestinal volvulus                          | 2                 |
| Abdominal trauma                             | 2                 |
| Extensive small bowel mucosal disease         | 35 (21.1)         |
| Crohn’s disease                              | 10                |
| Radiation enteritis                          | 12                |
| Chemotherapy related enteritis               | 9                 |
| Celiac disease                               | 4                 |
| Intestinal dysmotility                       | 32 (19.3)         |
| Post-operative                                | 15                |
| Systemic inflammatory                        | 9                 |
| Chronic intestinal pseudo-obstruction        | 8                 |
| Mechanical obstruction                       | 25 (15.1)         |
| Obluration (polypoid tumors, feces)          | 11                |
| Intrinsic bowel lesions (neoplastic, IBD, anastomotic) | 8               |
| Extrinsic lesions (abdominal adhesions, neoplasia, volvulus) | 6               |
| Intestinal fistula                           | 4 (2.4)           |
| Radiation enteritis                          | 2                 |
| Neoplastic                                    | 1                 |
| Trauma                                        | 1                 |
| Others                                        | 27 (16.3)         |
| Miscellaneous                                | 25                |
| Congenital diseases                          | 2                 |

Data are number of participants (%) or mean (SD) unless otherwise noted.

Body weight, body composition, PhA, and QoL were analyzed using one-way ANOVA. Logistic regression analysis was applied to assess which risk factors were correlated with survival. All statistical analysis was using SPSS 21.0 software (Statistical Program for Social Sciences, SPSS Inc, Chicago, IL, USA) and a value of $P < 0.05$ was considered statistically significant.

### RESULTS

A total of 262 patients were admitted to our clinical nutrition center between January 2016 and October 2018. According to the inclusion and exclusion criteria, 166 patients were finally included in the analysis (Figure 1).

#### Patient Population

In total, 166 patients (57.8% female, 42.2% male; mean age 46.2 ± 16.5 years) were enrolled. The main reasons for requiring HEN were short bowel syndrome (SBS) (25.9%), extensive small bowel mucosal disease (21.1%), intestinal dysmotility (19.3%), mechanical obstruction (15.1%), intestinal fistula (2.4%), and others (16.3%). The functional classification of IF was as follow: Type II (14.5%) and Type III (85.5%). Baseline characteristics are displayed in Table 1.

The majority of patients were fed by naso-intestinal tube (37.3%), nasogastric tube (42.2%), and percutaneous endoscopic gastrostomy/jejunostomy (PEG-J) (6.6%), and most infusions were pump infusion (83.1%) rather than bolus (9.6%). The mean duration of home enteral feeding (HEF) was within 3 months in 66.3% and 6 months in 33.7%. The main types of enteral nutrition products are standard type (Table 2).

#### Body Weight, Body Composition, and Phase Angle

Compared with the values before admission, the body weights, body composition, and PhA significantly increased during home enteral nutrition, especially within 3 months after discharge ($p < 0.05$) (Table 3). BIA analysis was also indicated that the

---

### TABLE 2 | Techniques used for HEN.

| GI tract access        | Number (%) |
|------------------------|------------|
| PEG-J                  | 11 (6.6)   |
| Nasogastric tube       | 70 (42.2)  |
| Naso-intestinal tube   | 62 (37.3)  |
| Jejunostomy            | 7 (4.2)    |
| Oral administration    | 16 (9.6)   |

**Mean duration of HEN (months) % of patients treated:**

- <1 months: 23 (13.9)
- 1–3 months: 87 (52.4)
- 3–6 months: 56 (33.7)

**Infusion technique (pts, %):**

- Bolus technique: 16 (9.6)
- Gravity set: 12 (7.2)
- Pump infusion: 138 (83.1)

**Person responsible for HEN:**

- Patient him/herself: 92 (55.4)
- Caregiver: 74 (44.6)

**Enteral diet used (%):**

- Standard: 113 (68.1)
- Fiber-rich: 5 (3.0)
- Protein-rich: 6 (3.6)
- Energy-dense: 2 (1.2)
- Diabetic: 6 (3.6)
- Oligopeptide: 25 (15.1)
- Blenderized diet: 9 (5.4)

Data are number of participants (%).

---
TABLE 3 | Body weight, body composition, and phase angle change.

| Variable       | Pre-hospital | First month after hospital discharge | Three months after hospital discharge | Six months after hospital discharge | p-value        |
|----------------|--------------|--------------------------------------|--------------------------------------|-----------------------------------|----------------|
| Weight (kg)    | 49.4 ± 10.8  | 55.5 ± 12.6                          | 54.4 ± 12.9                          | 53.8 ± 13.3                       | <0.001ab,c     |
| ICW (L)        | 18.26 ± 4.02 | 20.10 ± 4.51                         | 18.99 ± 4.51                         | 19.09 ± 4.36                      | 0.0020±,a      |
| ECW (L)        | 11.77 ± 2.42 | 12.63 ± 2.77                         | 12.17 ± 2.74                         | 12.51 ± 2.95                      | 0.020c         |
| TBW (L)        | 30.03 ± 6.33 | 32.72 ± 7.19                         | 31.16 ± 7.17                         | 31.61 ± 7.20                      | 0.006bc,d      |
| ECW/TBW (%)    | 0.39 ± 0.02  | 0.39 ± 0.02                          | 0.39 ± 0.02                          | 0.40 ± 0.02                       | <0.001bc,d,l   |
| TBW/FMM (%)    | 73.18 ± 0.57 | 73.06 ± 0.63                         | 73.12 ± 0.51                         | 73.26 ± 0.60                      | 0.018           |
| Protein (Kg)   | 7.89 ± 1.74  | 8.69 ± 1.95                          | 8.20 ± 1.95                          | 8.26 ± 1.90                       | 0.002          |
| Mineral (Kg)   | 3.10 ± 0.59  | 3.38 ± 0.76                          | 3.25 ± 0.72                          | 3.27 ± 0.71                       | 0.004bc         |
| FAT (Kg)       | 8.35 ± 5.38  | 10.71 ± 6.73                         | 11.82 ± 6.44                         | 10.62 ± 7.81                      | <0.001bc       |
| SLM (Kg)       | 38.41 ± 8.16 | 41.95 ± 9.25                         | 39.88 ± 9.22                         | 40.38 ± 9.19                      | 0.003d         |
| FFM (Kg)       | 41.01 ± 8.58 | 44.79 ± 9.83                         | 42.62 ± 9.78                         | 43.13 ± 9.72                      | 0.002bc,d      |
| SMM (Kg)       | 21.81 ± 5.24 | 24.21 ± 5.88                         | 22.75 ± 5.88                         | 22.90 ± 5.69                      | 0.002bc,a      |
| PBF (%)        | 16.34 ± 8.51 | 18.63 ± 9.66                         | 21.00 ± 8.95                         | 18.42 ± 10.99                     | <0.001c        |
| BCM (Kg)       | 26.15 ± 5.75 | 28.79 ± 6.46                         | 27.19 ± 6.45                         | 27.35 ± 6.24                      | 0.002bc,a      |
| BMC (Kg)       | 2.61 ± 0.50  | 2.84 ± 0.65                          | 2.73 ± 0.61                          | 2.75 ± 0.60                       | 0.004bc         |
| AC (cm)        | 22.86 ± 3.43 | 24.94 ± 4.44                         | 24.36 ± 3.50                         | 24.37 ± 4.95                      | <0.001bc,c      |
| AMC (cm)       | 19.28 ± 2.79 | 20.52 ± 3.29                         | 19.97 ± 2.51                         | 20.22 ± 4.09                      | 0.034          |
| Waist Cir. (cm)| 63.26 ± 7.18 | 65.41 ± 7.76                         | 66.68 ± 8.68                         | 66.07 ± 9.86                      | 0.003c         |
| VFA (cm²)      | 37.47 ± 22.22| 41.02 ± 28.06                        | 49.44 ± 30.92                        | 49.29 ± 38.04                     | <0.001bc,c      |
| RA phase angle | 4.57 ± 1.83  | 5.12 ± 2.20                          | 4.95 ± 1.50                          | 4.48 ± 1.39                       | 0.002bc,a      |
| LA phase angle | 4.38 ± 1.70  | 4.90 ± 2.46                          | 4.41 ± 1.07                          | 4.70 ± 3.57                       | 0.137          |
| TR phase angle | 5.74 ± 3.36  | 6.00 ± 2.64                          | 4.73 ± 1.92                          | 5.61 ± 4.27                       | 0.002bc,d      |
| RL phase angle | 4.89 ± 1.88  | 5.84 ± 2.08                          | 5.21 ± 1.89                          | 4.72 ± 1.74                       | <0.001bc,a,c    |
| LL phase angle | 4.84 ± 1.96  | 5.83 ± 2.05                          | 5.13 ± 1.80                          | 4.71 ± 1.82                       | <0.001a,b,d     |
| Average phase angle | 4.88 ± 1.85 | 5.54 ± 1.72                          | 4.81 ± 1.39                          | 4.84 ± 2.01                       | <0.001a,b,d     |

Data are mean (SD) unless otherwise noted. a, b, c, d, e, f indicates pair-wise differences were significant at p < 0.05. Where a, b indicates p < 0.05 for pre-hospital vs. first month after hospital discharge, b, c indicates p < 0.05 for pre-hospital vs. three months after hospital discharge, c, d indicates p < 0.05 for pre-hospital vs. 6 months after hospital discharge, d, e indicates p < 0.05 for first month after hospital discharge vs. 3 months after hospital discharge, e, f indicates p < 0.05 for first month after hospital discharge vs. six months after hospital discharge, and f, g indicates p < 0.05 for 3 months vs. 6 months after hospital discharge. ICW, intracellular water; ECW, extracellular water; TBW, total body water; SLM, soft lean mass; FFM, fat free mass; SMM, skeletal muscle mass; PBF, percent body fat; BCM, body cell mass; BMC, bone mineral content; AC, arm circumference; AMC, arm muscle circumference; Waist Cir., waist circumference; VFA, visceral fat area; RA, right arm; LA, left arm; TR, trunk; RL, right leg; LL, left leg; PHA, phase angle.

skeletal muscle mass, soft lean mass, and fat-free mass of body composition significantly improved (discharged at 6 months: skeletal muscle 21.81 ± 5.24 vs. 22.90 ± 5.69, p < 0.05; soft lean mass 38.41 ± 8.16 vs. 40.38 ± 9.19, p < 0.01; fat-free mass 41.01 ± 8.58 vs. 43.13 ± 9.72, p < 0.01) (Table 3).

Other Nutritional Parameters

At 1, 3, and 6 months after discharge, the serum concentrations of biochemical nutritional indicators (albumin, prealbumin, retinol binding protein, transferrin, fibronectin, and IGF-1) were significantly higher in HEN patients, compared with the pre-hospital values (p < 0.01) (Table 4).

Quality of Life

Overall, the reported health transition scores were improved at all three time points, with respect to baseline values (40.7 ± 12.1 vs. 57.4 ± 15.6 vs. 61.7 ± 17.6 vs. 69.3 ± 16.3, p < 0.001). The self-completed questionnaire includes 36 items, divided into eight domains (physical functioning [PF], role-physical [RP], bodily pain [BP], general health [GH], vitality [VT], social functioning [SF], role-emotional [RE], and mental health [MH]) scores, which also significantly improved during home enteral nutrition after discharge (p < 0.001) (Table 5).

Complications

Compared with the hospital treatment period, there were no significant increases in gastrointestinal, metabolic, or mechanical complications during HEN (p > 0.05) (Table 6).

Other Clinical Outcomes

The outcomes of the HEN therapy (moving from tube-feeding to oral feeding, received calories and protein from EN and work status) significantly improved at 6 months after discharge (Supplementary Table 1). There were 18 deaths in the study population (Supplementary Table 1). The results of logistic regression analysis indicate that the risk factors for mortality in malnourished patients with IF who were treated with HEN included advanced age (age >65 years), disease...
reduced food intake, malabsorption, and increased metabolism, issues in patients with IF. This disease could give rise to weight loss and the accompanying malnutrition are the major weight loss in patients with IF or intestinal insufficiency (type (cancer), and poor nutritional status (BMI < 16.5 kg/m²) (Supplementary Table 2).

**DISCUSSION**

Weight loss and the accompanying malnutrition are the major issues in patients with IF. This disease could give rise to reduced food intake, malabsorption, and increased metabolism, thereby increasing the risk of deteriorating nutritional status and ultimately negatively affecting clinical outcomes. Previous studies have shown the importance of enteral nutrition in reducing weight loss in patients with IF or intestinal insufficiency (25, 26). However, there is a lack of prospective studies evaluating the effects of long-term use of HEN in these patients.

In the present study, we assessed the effect of HEN on nutritional status, BC, PhA, and QoL in malnourished patients with IF. The results suggested that patients treated with HEN succeeded in maintaining stable body weight and body composition and PhA significantly increased during home enteral nutrition within the 1st month of discharge. Our results found that the serum concentrations of biochemical nutritional indicators (albumin, prealbumin, retinol binding protein, transferrin, fibronectin, and IGF-1) were significantly higher at 1, 3, and 6 months after discharge. Our results show that home enteral nutrition can improve nutritional status in patients with IF. We also identified changes in body composition and PhA in patients with intestinal failure in home enteral nutrition that no previous study has reported.

According to the ASPEN guidelines, BIA is a practical, portable, non-invasive body composition assessment tool (27). PhA can be used as an indicator of cell membrane quality and cell function (24). Low PhA is associated with increased number of readmissions, prolonged length of hospital stays, and deteriorated mortality in patients with intestinal failure (24). PhA may be a predictive factor for acute complications, muscle

**TABLE 4 | Other nutritional parameters.**

| Variable                     | Pre-hospital | First month after hospital discharge | Three months after hospital discharge | Six months after hospital discharge | p-value |
|------------------------------|--------------|--------------------------------------|---------------------------------------|-------------------------------------|---------|
| Albumin (g/L)                | 36.1 ± 6.6   | 37.1 ± 5.4                           | 41.2 ± 4.0                           | 39.9 ± 4.6                         | <0.001<sup>b,c,d,e</sup> |
| Prealbumin (mg/L)            | 159.5 ± 73.7 | 166.1 ± 62.0                         | 182.6 ± 81.4                         | 198.3 ± 71.8                       | <0.001<sup>c,e</sup> |
| Retinol binding Protein (mg/L)| 31.4 ± 14.7  | 31.3 ± 14.7                          | 35.1 ± 10.3                          | 39.3 ± 19.3                        | <0.001<sup>c,e</sup> |
| Transferrin (g/L)            | 2.23 ± 0.67  | 2.43 ± 0.64                          | 2.44 ± 0.78                          | 2.42 ± 0.70                        | 0.0230<sup>d</sup> |
| Fibronectin (mg/L)           | 192.3 ± 54.3 | 210.1 ± 33.0                         | 211.0 ± 59.9                         | 217.2 ± 39.7                       | 0.0010<sup>c</sup> |
| IGF-1 (ug/L)                 | 104.5 ± 88.6 | 139.6 ± 69.3                         | 191.6 ± 112.9                        | 170.5 ± 127.7                      | <0.001<sup>b,c,d</sup> |

Data are mean (SD) unless otherwise noted. a, b, c, d, e, f indicates pair-wise differences were significant at p < 0.05. Where a indicates p < 0.05 for pre-hospital vs. first month after hospital discharge, b indicates p < 0.05 for pre-hospital vs. 3 months after hospital discharge, c indicates p < 0.05 for pre-hospital vs. 6 months after hospital discharge, d indicates p < 0.05 for first month after hospital discharge vs. 3 months after hospital discharge, e indicates p < 0.05 for first month after hospital discharge vs. 6 months after hospital discharge and f indicates p < 0.05 for 3 months vs. 6 months after hospital discharge. IGF-1, insulin-like growth factor-1.

**TABLE 5 | HEN quality of life scores.**

| Variable | Pre-hospital | First month after hospital discharge | Three months after hospital discharge | Six months after hospital discharge | p-value |
|----------|--------------|--------------------------------------|---------------------------------------|-------------------------------------|---------|
| RHT      | 40.7 ± 12.1  | 57.4 ± 15.6                          | 61.7 ± 17.6                          | 69.3 ± 16.3                        | <0.001<sup>a,b,c,d,e</sup> |
| PF       | 45.4 ± 12.0  | 59.2 ± 11.5                          | 60.9 ± 15.0                          | 62.9 ± 16.7                        | <0.001<sup>a,b,c</sup> |
| RP       | 36.4 ± 12.5  | 55.6 ± 16.6                          | 58.7 ± 19.2                          | 59.0 ± 19.6                        | <0.001<sup>a,b,c</sup> |
| BP       | 56.2 ± 10.3  | 66.6 ± 10.0                          | 71.9 ± 14.2                          | 70.8 ± 14.3                        | <0.001<sup>a,b,d,e</sup> |
| SGH      | 51.7 ± 9.1   | 64.9 ± 10.5                          | 67.0 ± 12.5                          | 66.1 ± 14.4                        | <0.001<sup>a,b,c</sup> |
| VT       | 50.0 ± 9.0   | 63.7 ± 10.8                          | 66.7 ± 14.2                          | 66.8 ± 15.2                        | <0.001<sup>a,b,c</sup> |
| SF       | 56.7 ± 6.1   | 69.4 ± 7.6                           | 72.1 ± 9.9                           | 71.8 ± 10.2                        | <0.001<sup>a,b,c</sup> |
| RE       | 46.1 ± 16.2  | 71.1 ± 21.7                          | 73.4 ± 16.0                          | 70.5 ± 16.2                        | <0.001<sup>a,b,c</sup> |
| MH       | 42.4 ± 5.3   | 57.7 ± 9.1                           | 63.8 ± 17.5                          | 65.6 ± 18.3                        | <0.001<sup>a,b,f</sup> |

Data are mean (SD) unless otherwise noted. a, b, c, d, e, f indicates pair-wise differences were significant at p < 0.05. Where a indicates p < 0.05 for pre-hospital vs. first month after hospital discharge, b indicates p < 0.05 for pre-hospital vs. 3 months after hospital discharge, c indicates p < 0.05 for pre-hospital vs. 6 months after hospital discharge, d indicates p < 0.05 for first month after hospital discharge vs. 3 months after hospital discharge, e indicates p < 0.05 for first month after hospital discharge vs. 6 months after hospital discharge, and f indicates p < 0.05 for 3 months vs. 6 months after hospital discharge. RHT, reported health transition; PF, physical functioning; RP, role physical; BP, body pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; HEN, home enteral nutrition.
mass, and nutritional status (28). Indeed, we found that the PhA of patients with intestinal failure increased at 1 month and decreased at 3 and 6 months. These findings suggest that further researches are necessary to explore the physiologic and cellular mechanisms associated with PhA. However, due to the variability of body composition estimated within studies and the limited number of studies applying the same equipment, it was difficult to consolidate data by manufacturer to support summary statistics (27). It is urgent in future studies to cross verify the PhA values between devices of different brands or standardize their PhA values through device specific reference values, to enable comparisons of outcomes between studies applying different BIA devices (24, 29).

In the present study, we found that skeletal muscle mass, soft lean mass, and fat-free mass markedly increased with home enteral nutrition. It is well-known that as a highly plastic tissue, skeletal muscle is indispensable in human health and disease (30). Disease-related malnutrition is mainly manifested as decreased muscle mass and function, and this phenotype is related to loss of independence and decreased quality of life (30). Therefore, maintaining the quality of skeletal muscle is essential to achieve a normal nutritional status. The GLIM consensus has regarded skeletal muscle quality as the decisive criterion for diagnosing malnutrition due to its role in responding to trauma and disease (31, 32). This maintenance of body weight, body composition (skeletal muscle mass), PhA, and other nutritional indicators can be attributed to the increased caloric and protein intake from home enteral nutrition. The caloric intake was significantly higher in patients supported with HEN compared with baseline. Our results found a positive effect of home enteral nutrition on the up-regulation of IGF-I concentration. Previous research findings that IGF-1 contributes to enhance muscle function by increasing the production of muscle satellite cells and promoting the synthesis of muscle contractile proteins and mediator of muscle growth and repair (33, 34).

Compared with baseline values, the SF-36 scores, including the reported health transition, was significantly increased at 1, 3, and 6 months after discharge, suggesting that HEN improves QoL in patients with IF. The SF-36 score includes eight domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), all of which significantly improved. This finding is in line with those of other studies that suggested that HEN improves QoL (12, 35, 36). We speculate that the improvement of the patient’s quality of life is mainly related to the improvement of skeletal muscle mass and function and the improvement of nutritional status, although further evidence appears necessary to fully investigate this issue.

We found that there were no significant increases in gastrointestinal, tube, or mechanical complications during HEN compared with the hospital treatment period. This finding suggests that HEN is safe as well as effective in patients with IF; similar to the findings of a previous study (14). Of note, HEN was not associated with any severe adverse effects.

Although guidelines recommend gastrostomy or jejunostomy as the first choice when nutritional support is necessary for more than 2–3 months (37), the nasogastric tube is easier to maintain in the home setting and some patients or caregivers can place the nasogastric tube by themselves. In the present study, the most common mode of administration for enteral nutrition was nasogastric feeding (42.2%). This can probably be explained by its wide use for patients with enteral nutrition of short duration, such as those with malignancies and inflammatory bowel diseases. The gastrostomy was more frequently applied in neuromuscular and gastroesophageal diseases (38). Jejunostomy was an exceptional alternative in our experience, as reported in other studies, this operation is only available to patients with severe and persistent gastroesophageal reflux or gastric dysmotility (38).

Our research results suggest that commercially manufactured standard types of enteral nutrition are the main type of formula used. This is due to commercial enteral nutrition convenience and ease of use that makes them the preferred choice among patients requiring formula. In clinical practice, patients with normal basic gastrointestinal function are recommended to take polymeric enteral feeding. However, some patients with altered GI function may require specialized formulas (i.e., severe hepatic diseases and malabsorption). Another noteworthy finding in our research is the low level of use of special formula enteral nutrition (i.e., fiber-rich, protein-rich, and energy-dense), accounting for only 7.8% of all patients using enteral nutrition. This may be made clear by the fact that standard enteral nutrition is well-tolerated by most patients. There is a lack of data on the benefits of special formula enteral nutrition in IF patients. Gravity feeding was rare in our study. This feeding route is unfit for IF patients because the precise flow cannot be achieved and the delivery target volume cannot be adjusted. Moreover, continuous enteral feeding is largely used in patients for both tolerance and acceptability, and flow regulator pumps were required for most patients receiving HEN (38).
Our study has certain limitations. First, our study had a limited sample size and relative heterogeneity of disease types. Nevertheless, the main focus of our observational, descriptive study was clinical outcomes within 6 months after discharge. Second, we did not have complete collection information on home parenteral nutrition use over the study period, as well as parenteral nutrition use time, amount, and proportion, all of which may have potential impact on prognosis.

In conclusion, the results of our study support the importance of HEN in malnourished patients with IF. HEN helps maintain body weight, body composition, PhA, and nutritional status with minimal safety concerns and has a positive impact on the quality of life.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Research Ethics Committee of the Jinling Hospital. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

XW, XG, and JL equally contributed to the conception and design of the study. LZ and SL contributed to the design of the study. YZ contributed to the acquisition and analysis of the data. HL and DZ contributed to the analysis of the data. LZ contributed to the acquisition, analysis, and interpretation of the data. All authors drafted the manuscript, critically revised the manuscript, agreed to be fully accountable for ensuring the integrity and accuracy of the work, read, and approved the final manuscript.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (81470797, 81770531), the Science Foundation of Outstanding Youth in Jiangsu Province (BK20170009), the National Science and Technology Research Funding for Public Welfare Medical Projects (201502022), Military Medical Innovation Project (18CZX031), and The 13th Five-Year Plan Foundation of Jiangsu Province for Medical Key Talents (ZDRCA2016091).

**ACKNOWLEDGMENTS**

We thank Ruting Shen, Tingting Gao, and Paixu Chen for aiding data collection.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.643907/full#supplementary-material

**REFERENCES**

1. Pironi L, Arends J, Baxter J, Bozzetti F, Pelaez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr. (2015) 34:171–80. doi: 10.1016/j.clnu.2014.08.017
2. Pironi L, Cocos O, Forbes A, Holst M, Joly F, Jonkers C, et al. Intestinal failure in adults: Recommendations from the ESPEN expert groups. Clin Nutr. (2018) 37:1798–809. doi: 10.1016/j.clinu.2018.07.036
3. Gosselin KB, Duggan C. Enteral nutrition in the management of pediatric intestinal failure. J Pediatr. (2014) 165:1085–90. doi: 10.1016/j.jpeds.2014.08.012
4. Duggan CP, Jaksic T. Pediatric Intestinal Failure. N Engl J Med. (2017) 377:666–75. doi: 10.1056/NEJMr1602650
5. Le HD, Fallon EM, de Meijer VE, Malkan AD, Puder M, Gura KM. Innovative parenteral and enteral nutrition therapy for intestinal failure. Semin Pediatr Surg. (2010) 19:27–34. doi: 10.1053/j.sempedsurg.2009.11.004
6. Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, et al. ESPEN guideline on home parenteral nutrition. Clin Nutr. (2020) 39:1645–66. doi: 10.1016/j.clinu.2020.03.005
7. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. (2016) 35:247–307. doi: 10.1016/j.clinu.2015.09.013
8. Pittiruti M, Hamilton H, Biffi R, MacFie J, Perktovicz M. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). Clin Nutr. (2009) 28:365–77.
9. Neelis EG, Olleman JF, Hudst JM, de Koning BA, Wijnjen RM, Rings EH. Promoting intestinal adaptation by nutrition and medication. Best Pract Res Clin Gastroenterol. (2016) 30:249–61. doi: 10.1016/j.bpg.2016.03.002
10. Schörguber M, Fruehwald S. Effects of enteral nutrition on gastrointestinal function in patients who are critically ill. Lancet Gastroenterol Hepatol. (2018) 3:281–7. doi: 10.1016/S2468-1253(18)30036-0
11. Martin K, Gardner G. Home enteral nutrition: updates, trends, and challenges. Nutr Clin Pract. (2017) 32:712–21. doi: 10.1177/0884533617701401
12. Bischoff SC, Austin P, Boeykens K, Chourdakis M, Cuerda C, Jonkers-Schuiten C, et al. ESPEN guideline on home enteral nutrition. Clin Nutr. (2020) 39:5–22. doi: 10.1016/j.clinu.2019.04.022
13. Wong A, Banks MD, Bauer JD. A survey of home enteral nutrition practices and reimbursement in the Asia Pacific region. Nutrients. (2018) 10:214. doi: 10.3390/nu10020214
14. Wong A, Goh G, Banks M, Bauer J. A systematic review of the cost and economic outcomes of home enteral nutrition. Clin Nutr. (2018) 37:429–42. doi: 10.1016/j.clnu.2017.06.019
15. Santarpia L, Pagano MC, Pasanisi F, Contaldo F. Home artificial nutrition: an update seven years after the regional regulation. Clin Nutr. (2014) 33:872–8. doi: 10.1016/j.clnu.2013.10.005
16. Faruque SS, Parker EK, Talbot P. An evaluation of current home enteral nutrition services at principal referral hospitals in New South Wales, Australia. Aust Health Rev. (2016) 40:106–13. doi: 10.1071/AH15029
17. De Luis D, Izaola O, Cuellar L, Terroba M, Cabezas G, De La Fuente B. Experience over 12 years with home enteral nutrition in a healthcare area of Spain. J Hum Nutr Diet. (2013) 26:39–44. doi: 10.1111/j.1365-2776.2012.01208i
18. Shores DR, Alaih SM, Aucott SW, Bullard JE, Haney C, Tymann H, et al. Postoperative enteral nutrition guidelines reduce the risk of intestinal failure–associated liver disease in surgical infants. The J Pediatr. (2018) 195:140–7. doi: 10.1016/j.jpeds.2017.11.058
27. Sheean P, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition—an ESPEN Consensus Statement. Clin Nutr. (2015) 34:335–40. doi: 10.1016/j.clnu.2015.03.001
28. Olieman JF, Penning C, Ijsselstijn H, Escher JC, Joosten KF, Huls JM, et al. Utility of video consultation to improve the outcomes of home enteral nutrition in a population of frail older patients. Geriatr Gerontol Int. (2016) 16:762–7. doi: 10.1111/ggi.12551
29. Genton L, Norman K, Spoerri A, Pichard C, Karsegard VL, Herrmann D, et al. Bioimpedance-derived phase angle and mortality among older people. Rejuvenation Res. (2017) 20:118–24. doi: 10.1089/rej.2016.1879
30. Grosicki GJ, Fielding RA, Lustgarten MS. Gut microbiota contribute to age-related changes in skeletal muscle size, composition, and function: biological basis for a gut-muscle axis. Calcif Tissue Int. (2018) 102:433–42. doi: 10.1007/s00223-017-0345-5
31. Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition—a consensus report from the global clinical nutrition community. Clin Nutr. (2019) 38:1–9. doi: 10.1016/j.clnu.2018.08.002
32. Keller H, de van der Schueren MAE, Jensen GL, Barazzoni R, Compber C, Correia M, et al. Global leadership initiative on malnutrition (GLIM): guidance on validation of the operational criteria for the diagnosis of protein-energy malnutrition in adults. JPEN J Parenter Enteral Nutr. (2020) 39:2782–80. doi: 10.1016/j.pneno.2019.12.022
33. Philippou A, Maridaki M, Halapas A, Koutsilieris M. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo (Athens, Greece). (2007) 21:45–54.
34. Rondanelli M, Klersy C, Terracol G, Talluri J, Maugeri R, Guido D, et al. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elder people. Am J Clin Nutr. (2016) 10:830–40. doi: 10.3945/jcnp.115.113357
35. Gavazzi C, Colatruglio S, Valoriani F, Mazzaferro V, Sabbatini A, Biffi R, et al. Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: a multicentre randomised clinical trial. Eur J Cancer. (2016) 64:107–12. doi: 10.1016/j.ejca.2016.05.032
36. Wanden-Berghe C, Nolasco A, Sanz-Valero J, Planas M, Cuerda C, NADYA-SENPE G. Health-related quality of life in patients with home nutritional support. J Hum Nutr Diet. (2009) 22:219–25. doi: 10.1111/j.1365-277x.2009.00957.x
37. Löser C, Aschl G, Hebuterne X, Mathus-Vliegen E, Muscaritoli M, Niv Y, et al. ESPEN guidelines on artificial enteral nutrition—percutaneous endoscopic gastrostomy (PEG). Clin Nutr. (2005)24:848–61. doi: 10.1016/j.clnu.2005.06.013
38. Daveluy W, Guimber D, Mention K, Lescut D, Michaud L, Turck D, et al. The outcomes of long term home enteral nutrition (HEN) in older patients with severe dementia. Clin Nutr. (2019) 38:1871–6. doi: 10.1016/j.clnu.2018.07.010
39. Acosta-Escriban J, Fernández-Vivas M, Carmona TG, Caturla-Such J, García-Martínez M, Menendez-Mainer A, et al. Gastric versus transpyloric feeding in severe traumatic brain injury: a prospective, randomized trial. Intensive Care Med. (2010) 36:1532–9. doi: 10.1007/s00134-010-1908-3
40. Kosoku A, Uchida J, Nishide S, Kabei K, Shimada H, Iwai T, et al. Association of sarcopenia with phase angle and body mass index in kidney transplant recipients. Sci Rep. (2020) 10:1–8. doi: 10.1038/s41598-019-57195-z
41. Kohler M, Olesen SS, Rasmussen HH. Body composition predicts clinical outcome in patients with intestinal failure on long-term home parenteral nutrition. Clin Nutr ESPEN. (2018) 28:193–200.
42. Massironi S, Rossi RE, Cavalcoti FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr. (2013) 32:904–10. doi: 10.1016/j.clnu.2013.03.020
43. Öülenme JF, Penning C, Ijsselstijn H, Escher JC, Joosten KE, Huls JM, et al. Enteral nutrition in children with short-bowel syndrome: current evidence and recommendations for the clinician. J Am Diet Assoc. (2010) 110:420–6. doi: 10.1016/j.jada.2009.12.001
44. Sheean P, Gonzalez MC, Prado CM, McKeever L, Hall AM, Braunischweig CA. American society for parenteral and enteral nutrition clinical guidelines: the validity of body composition assessment in clinical populations. JPEN J Parenter Enteral Nutr. (2020) 44:12–43. doi: 10.1002/jpen.1669
45. Hui D, Bansal S, Morgado M, Dev R, Chisholm G, Bruer E. Phase angle for prognostication of survival in patients with advanced cancer: preliminary findings. Cancer. (2014) 120:2207–14. doi: 10.1002/cncr.28624
46. Genton L, Norman K, Spoerri A, Pichard C, Karasegard VL, Herrmann FR, et al. Bioimpedance-derived phase angle and mortality among older people. Rejuvenation Res. (2017) 20:118–24. doi: 10.1089/rej.2016.1879
47. Grosicki GJ, Fielding RA, Lustgarten MS. Gut microbiota contribute to age-related changes in skeletal muscle size, composition, and function: biological basis for a gut-muscle axis. Calcif Tissue Int. (2018) 102:433–42. doi: 10.1007/s00223-017-0345-5